PDCD1 and osteosarcoma: Studies have shown that blocking the interaction between PD-1 and PD-L1 with antibodies significantly improves the responsiveness of osteosarcoma to cytotoxic T lymphocytes (CTLs), leading to reduced tumor burden and increased survival rates in mouse models of metastatic osteosarcoma (54).